Explore the words cloud of the NeuroDeRisk project. It provides you a very rough idea of what is the project "NeuroDeRisk" about.
The following table provides information about the project.
|Coordinator Country||Austria [AT]|
|Total cost||9˙752˙062 €|
|EC max contribution||5˙331˙000 € (55%)|
1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
|Duration (year-month-day)||from 2019-03-01 to 2022-08-31|
Take a look of project's partnership.
|1||UNIVERSITAT WIEN||AT (WIEN)||coordinator||594˙450.00|
|2||ITA-SUOMEN YLIOPISTO||FI (KUOPIO)||participant||804˙900.00|
|3||FARMACEUTSKI FAKULTET UNIVERZITETAU BEOGRADU||RS (BELGRADE)||participant||696˙150.00|
|5||UNIVERSITE CLERMONT AUVERGNE||FR (CLERMONT-FERRAND)||participant||429˙400.00|
|6||A. PERSIDIS & SIA OE||EL (ATHINA)||participant||406˙800.00|
|7||ICETA INSTITUTO DE CIENCIAS, TECNOLOGIAS E AGROAMBIENTE DA UNIVERSIDADE DO PORTO||PT (PORTO)||participant||403˙500.00|
|8||UNIVERSITA DEGLI STUDI DI FIRENZE||IT (Florence)||participant||391˙500.00|
|9||MEDIZINISCHE UNIVERSITAET WIEN||AT (WIEN)||participant||372˙200.00|
|10||INTE:LIGAND SOFTWARE-ENTWICKLUNGS-UND CONSULTING GMBH||AT (MARIA ENZERSDORF)||participant||341˙400.00|
|11||UPPSALA UNIVERSITET||SE (UPPSALA)||participant||307˙400.00|
|12||ASTRAZENECA AB||SE (SODERTAELJE)||participant||0.00|
|13||FUJIFILM CELLULAR DYNAMICS INC||US (MADISON WI)||participant||0.00|
|14||MERCK SHARP & DOHME CORP||US (WHITEHOUSE STATION NJ)||participant||0.00|
|15||NOVARTIS PHARMA AG||CH (BASEL)||participant||0.00|
|16||PFIZER LIMITED||UK (SANDWICH)||participant||0.00|
|17||SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT||FR (Chilly Mazarin)||participant||0.00|
|18||UCB BIOPHARMA SRL||BE (BRUXELLES)||participant||0.00|
The adverse effects of pharmaceuticals on the central or peripheral nervous systems are poorly predicted by the current in vitro and in vivo preclinical studies performed during Research and Development (R&D) process. Therefore, increasing the predictivity of the preclinical toolbox is a clear need, and would benefit to human volunteers/patients (safer drugs) and Pharmaceutical Industry (reduced attrition). By combining top level scientists in neurobiology/toxicology with successful software developers, the NeuroDeRisk | Neurotoxicity De-Risking in Preclinical Drug Discovery Consortium will aim at tackling three of the most challenging adverse effects: seizures, psychological/psychiatric changes, and peripheral neuropathies. Our approach will be global, starting with an in-depth evaluation of knowledge on mechanisms of neurotoxicity (biological pathways as well as chemical structures and descriptors, using in particular historical data). Then we will search for innovative tools, assays and studies covering in silico, in vitro and in vivo approaches. This will include in particular: molecular design platform, artificial intelligence, human induced pluripotent stem cells, blood-brain-barrier models, immunohistochemistry, transcriptomics, RNA editing biomarkers, video-monitoring and telemetry of animals, pharmacokinetics, etc. The last step will aim at combining these tools in an integrated platform for better risk-assessment and decision-points throughout R&D process, and thus better protection of human volunteers and patients.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NEURODERISK" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "NEURODERISK" are provided by the European Opendata Portal: CORDIS opendata.
Bringing a prophylactic Ebola vaccine to licensureRead More
Boosting Ethionamide efficacy and lowering the dose with a small molecule transcriptional modulators, to overcoming MDR-TB infections and define a new place for Ethionamide in 1st-line TB treatments.Read More